HealthDay operates under the strictest editorial standards. Our syndicated news content is completely independent of any financial interests, is based solely on industry-respected sources and the latest scientific research, and is carefully fact-checked by a team of industry experts to ensure accuracy.
- All articles are edited and checked for factual accuracy by our Editorial Team prior to being published.
- Unless otherwise noted, all articles focusing on new research are based on studies published in peer-reviewed journals or issued from independent and respected medical associations, academic groups and governmental organizations.
- Each article includes a link or reference to the original source.
- Any known potential conflicts of interest associated with a study or source are made clear to the reader.
Please see our Editorial and Fact-Checking Policy for more detail.Editorial and Fact-Checking Policy
HealthDay Editorial Commitment
HeathDay is committed to maintaining the highest possible levels of impartial editorial standards in the content that we present on our website. All of our articles are chosen independent of any financial interests. Editors and writers make all efforts to clarify any financial ties behind the studies on which we report.
TUESDAY, March 13 (HealthDay News) -- Men with acute ischemic stroke are more likely to benefit from tissue-plasminogen activator than women, researchers report in the March 13 issue of Neurology.
Mitchell S.V. Elkind, M.D., of Columbia University Medical Center in New York City, and colleagues measured predictors of outcome in 333 patients treated with recombinant tissue-plasminogen activator (rtPA) in a multicenter, randomized, placebo-controlled study of acute stroke treatment.
The investigators found that 47.5 percent of men achieved good functional outcomes, measured by the Barthel Index and Rankin Score, three months after treatment compared with only 30.3 percent of women. The sex-specific differences remained even after adjusting for multiple covariates.
"Women are definite candidates for treatment with tPA, which is still our only approved medical treatment for acute ischemic stroke," Elkind said in a prepared statement. "It cannot be overemphasized enough that these are secondary findings from a study done for other purposes. More research is needed to confirm these findings, and to determine why women may not respond as well as men to the treatment."
GlaxoSmithKline provided funding for the original trial and many of the authors have other pharmaceutical company affiliations.
This story may be outdated. We suggest some alternatives.
The content contained in this article is over two years old. As such our recommendation is that you reference the articles below for the latest updates on this topic. This article has been left on our site as a matter of historic record. Please contact us at email@example.com with any questions.